cyclopentane has been researched along with Liver Steatosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, H; Chu, Y; Feng, B; Huang, Y; Li, H; Liu, H; Liu, J; Wu, Y; Xiang, Q; Yuan, X; Zhang, C; Zhang, Y; Zhao, B; Zhao, X | 1 |
1 other study(ies) available for cyclopentane and Liver Steatosis
| Article | Year |
|---|---|
The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Benzylidene Compounds; Blood Glucose; Body Weight; Cell Membrane; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cyclopentanes; Cytokines; Enzyme Inhibitors; Fatty Liver; Gene Expression Regulation; Gluconeogenesis; Glucose Tolerance Test; Glucose Transporter Type 4; Insulin Resistance; Intra-Abdominal Fat; Liver; Male; Mice; Obesity; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; RNA, Messenger; Signal Transduction | 2016 |